How Marijuana-Focused Biotech Companies Have Performed in 2018

The biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Insys Therapeutics (INSY), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), and 22nd Century Group (XXII).

In this article, we’ll discuss the stock price performances of these companies YTD (year-to-date).

The chart above compares the normalized stock prices of the above-mentioned companies YTD.

GW Pharmaceuticals is a biotechnology company. Its stock price has risen ~12.8% YTD, while it’s risen 32.9% in the last 12 months to close at $148.09 on November 8.

Insys Therapeutics is a commercial-stage specialty pharmaceutical company. Insys Therapeutics’ stock price has fallen ~17.1% YTD, while the stock has risen 58.4% in the last 12 months to close at $7.97 on November 8.

Cara Therapeutics is a clinical-stage biotechnology company. Cara Therapeutics’ stock price has risen ~66.9% YTD, while it’s risen 62.1% over the last 12 months to close at $20.43 on November 8.

22nd Century Group is a plant biotechnology company. Its stock has risen ~6.1% YTD and 27.7% over the last 12 months to close at $2.63 on November 8.

Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company. Its stock price has fallen ~3.2% YTD, and it’s risen 1.1% over the last 12 months to close at $6.87 on November 8.

We’ll discuss analysts’ estimates, recommendations, and revenue estimates for these companies later in the series.

The iShares NASDAQ Biotechnology ETF (IBB) holds 0.5% in GW Pharmaceuticals, 0.1% in Insys Therapeutics, 0.1% in Cara Therapeutics, and 0.1% in Corbus Pharmaceuticals.